CDC-RFA-DP22-2204: Improving and Enhancing the US Vision and Eye Health Surveillance System
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCCDPHP notices from 2022.
Centers for Disease Control - NCCDPHP offered grants of up to $850,000 (at least $425,000) to any type of organization. It expected to make one award worth $2.5 million in total. Applications closed on March 14, 2022.
From the official notice on Grants.gov, last changed January 7, 2022. Checked November 7, 2026.
- Award ceiling$850,000
- Award floor$425,000
- Total funding$2.5 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | January 7, 2022 |
|---|---|
| Deadline | March 14, 2022 |
| Archived by Grants.gov | April 13, 2022 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Not applicable.
Is this a realistic fit?
- Past Chronic Diseases: Research, Control, and Prevention awards averaged $651,162; this notice allows up to $850,000 per award.
- Most of the program's money (35% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
This NOFO solicits non-research cooperative agreement applications to enhance CDC’s Vision and Eye Health Surveillance System (VEHSS), using data from a variety of sources, in order to assess U.S. national-, state-, and county-level prevalence of major eye diseases, vision impairment, and utilization of eye care. The strategies and activities in this NOFO focus on maintaining, improving, and enhancing the VEHSS, which is the only interactive, comprehensive collection of vision and eye health data in the United States. The VEHSS includes data from 5 national surveys, 4 administrative claims databases, an electronic health record registry, and published examination studies. Important activities of this NOFO include adding new years of data, streamlining indicators, identifying data gaps, and prioritizing data sources and key indicators that have the greatest value for public health surveillance. The project will also identify and add other sources of vision and eye health data, for example, data from Veterans Affairs, Indian Health Service, and other electronic health record systems. The NOFO will incorporate into the VEHSS national-, state-, and county-level data on social determinants of health and improve functionality of the VEHSS and end-user experience by enhancing data visualization and presentation. Lastly, this project will focus on outreach and dissemination of the VEHSS to key partners to drive an increase in end-user engagement with the surveillance system.
Who has won Chronic Diseases: Research, Control, and Prevention grants before
From fiscal 2021 to 2025, Chronic Diseases: Research, Control, and Prevention (93.068) awarded $57.3 million across 88 grant awards, an average of $651,162 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| New York University | New York | 3 | $5.6 million |
| American College of Rheumatology, Inc | Georgia | 1 | $4.9 million |
| Lupus Foundation of America Inc. | District of Columbia | 1 | $4.8 million |
| National Opinion Research Center | Illinois | 2 | $3.2 million |
| Cicatelli Associates, Inc. | New York | 1 | $3.0 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DP22-2204 still open?
No. It closed on March 14, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Improving and Enhancing the US Vision and Eye Health Surveillance System?
Centers for Disease Control - NCCDPHP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Improving and Enhancing the US Vision and Eye Health Surveillance System?
Closed March 14, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $850,000 each. About $2.5 million in total for one award.
Who has won Chronic Diseases: Research, Control, and Prevention grants before?
The largest recipients over five fiscal years were New York University, American College of Rheumatology, Inc, Lupus Foundation of America Inc. The program made 88 awards worth $57.3 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)